You are here

  • Home
  • Archive
  • Volume 75, Issue 11
  • Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Khamashta M, Merrill JT, Werth VP on behalf of the CD1067 study investigators, et al
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Annals of the Rheumatic Diseases 2016;75:1909-1916.